Assessment of coenzyme Q10 tolerability in Huntington's disease

Movement Disorders

Volumn 11, Issue 3, 1996, Pages 321-323

  Feigin, A ^a,b   Kieburtz, K ^a   Como, P ^a   Hickey, C ^a   Claude, K ^a   Abwender, D ^a   Zimmerman, C ^a   Steinberg, K ^a   Shoulson, I ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Coenzyme Q10; Huntington's disease

Indexed keywords

UBIDECARENONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEADACHE; HEARTBURN; HUMAN; HUNTINGTON CHOREA; INTERVIEW; INVOLUNTARY MOVEMENT; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RATING SCALE; TELEPHONE; TIME;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; TREATMENT OUTCOME; UBIQUINONE;

EID: 0029988363     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110317     Document Type: Article

References (19)

1. Hayden MR. Huntington's chorea. Berlin: Springer-Verlag, 1981.
2. Shoulson I. Huntington's disease: cognitive and psychiatric features. Neuropsychiatry Neuropsychol Behav Neurol 1990;3:15-22.
3. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577.
4. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
5. Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset of Huntington's disease. Nature Genet 1993;4:387-392.
6. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130.
7. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992;42:733-738.
8. Mettler FA. Choreoathetosis and striatopallidal necrosis due to sodium azide. Exp Neurol 1972;34:291.
9. Beal MF, Swartz KJ, Hyman BT, et al. Aminooxyacetic acid results in excitotoxic lesions by a novel indirect mechanism. J Neurochem 1991;57:1068.
10. Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 1983;13:72.
11. Mann VM, Cooper JM, Javoy-Agid F, et al. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990;336:749.
12. Koroshetz WJ, Jenkins B, Rosen B, et al. Ubiquinone lowers occipital lactate levels in patients with Huntington's disease [Abstract]. Neurology 1993;43(suppl 4):334.
13. Shoulson I, Fahn S. Huntington's disease: clinical care and evaluation. Neurology 1979;29:1-3.
14. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259.
15. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery. Tucson: Neuropsychology Press, 1985.
16. Wechsler D. A standardized memory scale for clinical use. J Psychol 1945;19:87-95.
17. Spreen O, Benton AL. Neurosensory center comprehension examination for aphasia (NCCEA). Revised ed. Victoria, Ontario, Canada: University of Victoria, Neuropsychology Laboratory, 1977.
18. Smith A. Symbol digit modalities test manual. Los Angeles: Western Psychological Services, 1982.
19. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.